Stocksigma LogoStocksigma Logo

Ind-Swift Laboratories Reports Nil Deviation in Convertible Warrants Fund Utilization

Ind-Swift Laboratories confirmed zero deviation in proceeds utilization for the quarter ended 30th Sep'26 regarding its preferential issue of 70 lakh fully

Ind-Swift Laboratories Reports Nil Deviation in Convertible Warrants Fund Utilization

Ind-Swift Laboratories Ltd 路 Others (Uncategorized) 路 30 Oct 2026, 2:15 am

Ind-Swift Laboratories Reports Nil Deviation in Convertible Warrants Fund Utilization Ind-Swift Laboratories confirmed zero deviation in proceeds utilization for the quarter ended 30th Sep'26 regarding its preferential issue of 70 lakh fully convertible warrants allotted on 17th Sep'26. Out of the total issue size of Rs. 137.20 crore, the company raised Rs. 34.30 crore and deployed Rs. 15.60 crore. Key capital outlays include Rs. 6.31 crore for manufacturing expansion and warehousing, Rs. 4.85 crore for subsidiary investments, Rs. 3.99 crore toward working capital, Rs. 0.33 crore for R&D, and Rs. 0.11 crore for general corporate purposes.

Original exchange filing (PDF)

More announcements from Ind-Swift Laboratories Ltd

All Ind-Swift Laboratories Ltd announcements